Fig. 6: MCL1 pharmacological inhibitors suppress mTORC1.
From: MCL1 modulates mTORC1 signaling to promote bioenergetics and tumorigenesis
Immunoblotting analysis of lysates derived from CHL-1 cells (A–C) or SK-MEL30 cells (D, E) treated with the indicated concentrations of MCL1 inhibitors ABBV-467, UMI-77 or as control ABT-737 for 48 h. The samples derived from the same experiment but different gels for pS6K1, pS6 and another for S6K1, S6 were processed in parallel. F Immunoblotting analysis of lysates derived from CHL-1 cells treated ABBV-467 (10 nM), UMI-77 (10 μM) or ABT-737 (10 μM) for the indicated time points. The samples derived from the same experiment but different gels for pS6 and pS6K, another for S6K1 and another for S6 were processed in parallel.
